Clinical Trial Update: Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluating a single dose of intravenous recombinant human TNF-α with liposomal doxorubicin in patients with advanced solid tumors or lymphomas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• liposomal doxorubicin (doxorubicin liposomal)
• rhTNF-α (recombinant human tumor necrosis factor-alpha)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Solid Tumors, Lymphomas | Phase 1 | Status: WITHDRAWN